Key Highlights

  • Vericel (NASDAQ:VCEL) closed at USD 53.40 in the November 5, 2026 session, a 17.40% rise on the day that sits alongside 27.16% over one week and 29.04% over one month.
  • Third quarter Revenue reached USD 85.4 million, lifting 26% from USD 67.5 million, while Net Income jumped 179% to USD 14.2 million and diluted EPS rose to USD 0.27 from USD 0.10.
  • The 2026 revenue range was raised to USD 344 million to USD 346 million from USD 330 million to USD 340 million, and the adjusted EBITDA Margin outlook moved to 28% from 27%.
  • Shares are also higher by 19.11% over three months and 53.70% over six months, so the latest move extends a longer climb.

Quarterly Revenue Mix Behind the Weekly Surge

Vericel (NASDAQ:VCEL) saw its figures laid out in the company release dated November 5, 2026, which listed MACI revenue at USD 67.4 million, a 21% increase from USD 55.7 million, while Epicel generated USD 12.7 million, up 23% from USD 10.4 million. Burn Care revenue climbed 52% to USD 18.0 million, with NexoBrid sales of USD 2.3 million (USD 1.5 million a year earlier) and BARDA procurement revenue of USD 3.0 million. Adjusted EBITDA came to USD 25.2 million, equal to 30% of revenue against 25% a year earlier. Management also said MACI Arthro logged its highest case count in any quarter since launch. Working back from the 17.40% one-day gain, the prior close was roughly USD 45.49 (calculated).

Beat and Raise Logic Behind the Mid cap Re-Rating

The move rests on an Earnings beat combined with a higher forecast. The revised revenue band of USD 344 million to USD 346 million lifts the midpoint by USD 10 million, roughly 3.0% (calculated), and the 28% margin goal feeds straight into EBITDA projections. When profit expands faster than sales, here 179% net income growth against 26% revenue growth, analysts commonly lift forward earnings estimates, and a valuation multiple applied to a bigger earnings base can push the share price higher again. This describes how such re-ratings generally work, not a forecast. Cash and investments of USD 235.6 million with no Debt reduce Balance Sheet risk.

Valuation Context, Liquidity and Downside Exposure

Expectations are higher after a 29.04% monthly advance. Mid cap shares, generally valued between USD 2 billion and USD 10 billion, usually trade with more depth than small caps, yet a 17.40% single-day jump can unwind if estimates level off or MACI case growth cools. MACI supplied about 79% of the quarter's revenue (calculated, USD 67.4 million of USD 85.4 million), so any reimbursement or surgeon adoption setback would matter a great deal. BARDA procurement income of USD 3.0 million can vary sharply between quarters. Year to date performance, the 52-week range and average Volume were not verified.

Where Things Stand

Not on its own. Vericel (NASDAQ:VCEL) rallied because record third quarter results and a raised 2026 outlook arrived together. A published market data snapshot places the stock among the stronger mid caps of the past week at 27.16%. At USD 53.40 the shares are 19.11% above their three month level and 53.70% above their six month level. Some of the one-day 17.40% advance may simply reflect repricing that already took place. Watchers should compare the next quarterly MACI growth with the 21% reported this period and check whether the 28% margin target survives. Nothing here implies the move will continue.